Lilly Calytrix Acquisition: $1.5B Bet on a Blood Cancer Mutation
Eli Lilly will pay up to $1.5 billion for Calytrix Bio and its preclinical mutant-CALR antibody for essential thrombocythemia and myelofibrosis.
Eli Lilly will pay up to $1.5 billion for Calytrix Bio and its preclinical mutant-CALR antibody for essential thrombocythemia and myelofibrosis.